第62届欧洲肾脏协会大会：耐赋康®最新研究结果为“全部治疗”IgA肾病新管理策略奠定基础，实现IgA肾病全人群肾脏保护

Core Insights - The studies presented at the 62nd European Renal Association (ERA 2025) conference confirm the efficacy of Nefeccon (Budesonide delayed-release capsules) in protecting kidney function across various baseline eGFR levels and different pathological changes in patients with IgA nephropathy [2][3][5] Study Findings - The NefIgArd study sub-analysis demonstrated that Nefeccon significantly reduces baseline urine protein-to-creatinine ratio (UPCR) regardless of the baseline eGFR level, showing protective effects on eGFR at all time points [3][6] - A second multicenter study focused on the treatment benefits for IgA nephropathy patients with different pathological manifestations, revealing that after 9 months of Nefeccon treatment, patients exhibited significant reductions in urine protein and stable eGFR, particularly in those with endothelial cell proliferation (E1) and/or crescent formation (C1) [4][10] Clinical Implications - Nefeccon is the first and only IgA nephropathy treatment approved in China, the US, and Europe that is not limited by proteinuria levels, supporting a "treat all" strategy for kidney protection in IgA nephropathy patients [2][5] - The findings provide strong evidence for early initiation of cause-targeted therapy upon diagnosis to protect kidney function and improve overall prognosis for all patients [3][10] Market Context - The prevalence of IgA nephropathy is significantly higher in Asia, with an estimated 5 million patients in China and over 100,000 new cases diagnosed annually, indicating a substantial unmet clinical need [4][5]